Skip to main content
OpenTrials
Completed

NCT Number: NCT07036809

Assessment of Antithrombin III, Protein C, Protein S and D-dimer in Acute Leukemia

The goal of this observational study is to evaluate the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Leukemia (Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)). The main questions it aims to answer are:

What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Lymphoblastic Leukemia? What are the levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients with Acute Myeloid Leukemia? Researchers will compare patients with Acute Leukemia (30 with ALL and 30 with AML) to 30 healthy control subjects to see if there are significant differences in the levels of Antithrombin III, Protein C, Protein S, and D-dimer.

Participants will:

Undergo full history and clinical examination. Have routine hematological analysis including Complete Blood Count (CBC), blood film, Erythrocyte sedimentation rate (ESR), Prothrombin Time Test and INR (PT/INR), and partial thromboplastin time (PTT).

Have specific tests for quantitative measurement of Antithrombin III, Protein C, Protein S, and D-dimer.

Undergo Flow cytometry immunophenotyping.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acute Leukemia

Sex eligibility

All sexes

Study type

Observational

Primary location

Al-Hussein University Hospital

Cairo, 11633, Egypt

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with leukemia in group 1 and 2.
  • willing to participate in the study.

Exclusion criteria

  • refusing to participate.
  • patients with know to have either hereditary thrombophilia or current thrombosis.

Treatment and study plan

Antithrombin III

Diagnostic Test

quantitative measurement(%)

Protein C

Diagnostic Test

quantitative measurement(%)

Protein S

Diagnostic Test

quantitative measurement(%)

D-dimer

Diagnostic Test

quantitative measurement( ug/ml)

Flow cytometry immunophenotyping

Diagnostic Test

Flow cytometry immunophenotyping

Primary outcomes

  1. Assessment of Antithrombin III, Protein C, Protein S, and D-dimer Levels in Acute Leukemia Patients

    Time frame: at the time of patient recruitment for the study.

    To evaluate and compare the quantitative levels of Antithrombin III, Protein C, Protein S, and D-dimer in patients diagnosed with Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML) against healthy control subjects. This assessment will help determine any significant differences in these coagulation parameters within the different acute leukemia subtypes and in comparison to healthy individuals.

Sponsors and collaborators

Lead sponsor

Muhamed Ahmed Abdelmoaty Muhamed Alhagrasy

Other

Registry information

Important dates

Study start
2023
Primary completion
2025
Study completion
2025
First posted
Jun 25, 2025
Registry last updated
Jan 29, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.